STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
504actual
Sites
74
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-28 | actual | When the study began enrolling |
| Primary completion | 2026-05-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-13 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Severe Eosinophilic Asthma
Intervention
- Drug: Benralizumab — also filed as Fasenra
Primary outcome
what the primary-completion date above is the date OFTo assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen in the overall patient populationa and by subgroups of baseline background therapy
measured within 40 weeks after the first administration
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed